Study for Atrial Fibrillation
(ADVENTPAS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System for individuals with paroxysmal atrial fibrillation, a type of irregular heartbeat that does not improve with standard medications. The study is observational, tracking outcomes after treatment to assess its effectiveness in real-world settings. It suits individuals who have tried at least one medication for their irregular heartbeat without success. Participants must attend regular follow-ups and testing at the study sites. As an unphased study, this trial provides a unique opportunity to contribute to understanding the real-world effectiveness of this treatment.
Why are researchers excited about this trial?
Without specific details about the treatment or condition that the ADVENT Post Approval Study is targeting, we can't dive into the specifics of what makes it unique. However, researchers are generally excited about new treatments in clinical trials because they often offer novel approaches or improvements over existing therapies. This could include a new mechanism of action that targets the condition more precisely, a new delivery method that improves how the drug is administered and absorbed, or a new active ingredient that could be more effective or have fewer side effects. These innovations have the potential to enhance patient outcomes and provide options where current treatments may fall short.
Who Is on the Research Team?
Stavros E Mountantonakis, MD, MBA
Principal Investigator
Northwell Health, Lenox Hill Hospital
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo pulmonary vein isolation using the FARAPULSE Pulsed Field Ablation System
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of serious adverse events and treatment success
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boston Scientific Corporation
Lead Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology